GlaxoSmithKline (GSK) has secured a positive recommendation from a European Medicines Agency (EMA) panel for its Nucala (mepolizumab) medication.
The drug is designed for self-administration using a pre-filled pen or safety syringe.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
First approved in 2015 for the treatment of severe eosinophilic asthma, Nucala is a monoclonal antibody (mAb) designed to target IL-5 and decrease blood eosinophils. It is intended for treating conditions that are driven by eosinophil-caused inflammation.
Assessed in 16 clinical trials across various eosinophilic indications, Nucala has secured approval as an add-on maintenance therapy for eosinophilic asthma in more than 20 markets, including the US and Europe. It has received approval as an add-on maintenance treatment for eosinophilic granulomatosis with polyangiitis (EGPA) patients in countries such as the US, Japan and Canada.
Nucala 100mg solution in pre-filled pen and pre-filled syringe are suitable for adults and adolescents.
The positive opinion from the EMA’s Committee for Medicinal Products for Human Use (CHMP) is based on results from two open-label, single-arm, Phase IIIa clinical trials. These studies investigated the real-world use of the administration options in clinic and at-home by severe eosinophilic asthma patients or their caregivers.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataPatients in both trials were able to successfully self-administer treatment with the pre-filled pen, as well as pre-filled safety syringe following appropriate training.
The trials found that most patients preferred at-home options compared to in-clinic administration.
In addition, an open-label, parallel-group, single-dose pharmacokinetic (PK) and pharmacodynamic (PD) study validated that the administration options were comparable to the lyophilised version, noted GSK.
